3 Reasons to Buy Pfizer Stock Now

Core Viewpoint - Pfizer is experiencing a potential turnaround after years of underperformance, with several factors making its stock attractive despite recent struggles [2][10] Group 1: Acquisition and Product Development - Pfizer's recent acquisition of Metsera for approximately $5 billion aims to enhance its portfolio in the growing anti-obesity market, with Metsera's leading candidate, MET-097i, showing promising results in clinical trials [3][4] - MET-097i demonstrated a 14.1% weight loss over 28 weeks in trials, with only 2.9% participant dropout, indicating strong efficacy and tolerability compared to existing GLP-1 drugs [4][5] - The long-acting nature of MET-097i, requiring monthly administration, could attract more patients compared to current weekly options, pending confirmation in phase 3 studies [5] Group 2: Strategic Agreements and Cost Management - Pfizer secured a three-year exemption from tariffs through a deal with the U.S. government, allowing it to sell certain drugs at lower costs while expanding its manufacturing footprint [7] - The company is targeting net cost savings of $4.5 billion by the end of 2025, with additional savings expected through 2027, to improve profitability [8] Group 3: Valuation and Market Position - Pfizer's stock is currently trading at 8.8 times forward earnings, significantly lower than the healthcare industry's average of 17.3 times, suggesting it may be undervalued despite recent challenges [10]